Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.48 USD | +0.68% | -1.33% | +5.71% |
Mar. 25 | Artelo Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Feb. 06 | Top Premarket Gainers | MT |
Strengths
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+5.71% | 4.69M | - | - | |
+2.73% | 108B | B+ | ||
+9.59% | 104B | B+ | ||
+6.58% | 23.66B | B | ||
-12.59% | 22.1B | B+ | ||
-3.29% | 19.71B | A- | ||
-35.36% | 18.2B | A- | ||
-13.29% | 16.19B | B | ||
+4.68% | 13.72B | C+ | ||
+34.25% | 12.22B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock
- Equities
- Stock Artelo Biosciences, Inc. - Nasdaq
- Ratings Artelo Biosciences, Inc.